best stock buys

James and Carrie Finan have been house-hunting in the Seattle area for four months in a seemingly futile race against time: Theyre living in a room in James mothers house and their first child is due in September.

Theyve seen about 40 starterhouses that match their criteria$350,000 or less, three bedrooms, about 1,200 square feet — and made four offers ranging from $32,000 to $82,000 above asking price. Theyve lost out each time.

Every time we hear were not getting it, my heart kind of sinks, James, 29, says. Its been insane.

A big reason the Finans are struggling is the regulatory morass faced by builders like Mike Walsh. On a parcel in Sammamish, Wash., a Seattle suburb, he wouldlike to build 36 relatively affordable houses. But since zoning changes in recent years permit just 25, hell have to sell each at $1.2 million to make the project profitable.

best stock buys: Myriad Genetics, Inc.(MYGN)

Advisors’ Opinion:

  • [By Cory Renauer]

    Shares of Myriad Genetics, Inc. (NASDAQ:MYGN), a DNA diagnostics specialist, dropped 61.4% last year, according todata from S&P Global Market Intelligence.Efforts to offset hereditary cancer-testing segment losses just weren’t successful enough to keep profits, and the stock, from sliding last year.

best stock buys: PowerShares S&P SmallCap Information Technology Portfolio(PSCT)

Advisors’ Opinion:

  • [By ]

    On this chart, I plotted the year-to-date performance of the Nasdaq Composite index against two exchange-traded funds (ETFs) — one is an ETF that tracks the small-cap Russell 2000 index, and the other is PowerShares S&P SmallCap Information Technology Portfolio ETF (Nasdaq: PSCT), which serves as a proxy for the types of small-cap tech stocks that are a focus of my premium newsletter, Game-Changing Stocks.

  • [By ]

    Overall, our Game-Changing Stocks portfolio has had a good run this year. Our closed positions for 2017 have, on average, returned 28.5% — a much stronger result than what we’ve seen from the Russell 2000 index or from the PowerShares S&P Small Cap Information Technology Portfolio ETF (Nasdaq: PSCT), which returned 13% and 11% year-to-date, respectively. It’s not a fair comparison, of course, because our closed positions all have different time frames, but it does stress the strong promise of game-changing stocks.

best stock buys: OneBeacon Insurance Group, Ltd.(OB)

Advisors’ Opinion:

  • [By Monica Gerson]

    The list of below stocks is notable as the shares have traded on sequentially increasing volume spanning the trading days from September 16 to September 20:

best stock buys: BioCryst Pharmaceuticals Inc.(BCRX)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Loxo Oncology Inc (NASDAQ: LOXO) rose 32.7 percent to $65.00 in pre-market trading after the company reported that larotrectinib trial demonstrated 76 percent confirmed objective response rate.
    Dynavax Technologies Corporation (NASDAQ: DVAX) shares rose 22 percent to $7.20 in the pre-market trading session after the company on Friday presented updated data for SD-101 in combination with KEYTRUDA.
    Puma Biotechnology Inc (NASDAQ: PBYI) rose 21.7 percent to $99.75 in pre-market trading as the company disclosed positive PB272 Phase 2 data from TBCRC 022 trial at ASCO17.
    Helios and Matheson Analytics Inc (NASDAQ: HMNY) shares rose 20.7 percent to $3.21 in pre-market trading after the company reported that RedZone has acquired all the assets of Trendit including three technology patents.
    Forestar Group Inc. (NYSE: FOR) rose 13.1 percent to $16.05 in pre-market trading after D.R. Horton, Inc. (NYSE: DHI) proposed to buy 75 percent of Forestar Group for $16.25 per share in cash.
    TG Therapeutics Inc (NASDAQ: TGTX) shares rose 12 percent to $15.50 in pre-market trading after the company said Phase 3 GENUINE trial met primary endpoint with TG-1101 + ibrutinib increasing overall response rate by >70 percent versuss ibrutinib alone.
    Gigamon Inc (NYSE: GIMO) gained 10.8 percent to $43.55. Reuters reported that Gigamon is exploring a potential sale.
    BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) rose 8.7 percent to $6.00 in pre-market trading after the company announced Rapivab pediatric sNDA acceptance by the FDA.
    Array Biopharma Inc (NASDAQ: ARRY) rose 7.2 percent to $8.77 in pre-market trading after gaining 5.68 percent on Friday.
    Ehi Car Services Ltd (ADR) (NYSE: EHIC) shares rose 6.4 percent to $10.76 in pre-market trading. eHi Car Services posted Q1 earnings of $0.06 on sales of $89.43 million.
    Skyworks Solutions Inc (NASDAQ: SWKS) rose 5.9 percent to $114.79 in pre-market trading after gaining 0.69 percent on Friday.
    Sorl Auto
  • [By Sean Williams]

    Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX), a biotech company that develops small-molecule drugs to block enzymes involved in disease proliferation, surged as much as 12% today after a report was issued that a highly pathogenic H5N1 bird flu was found in the northern part of Malaysia.

  • [By Monica Gerson]

    BioCryst Pharmaceuticals (NASDAQ: BCRX) shares gained 5.98% to $6.91 in the pre-market session after the company has been awarded contract by the National Institute of Allergy and Infectious Diseases to develop BCX4430 for the treatment of Marburg virus disease.

best stock buys: Lifetime Brands Inc.(LCUT)

Advisors’ Opinion:

  • [By Lisa Levin]

    On Monday, cyclical consumer goods & services shares gained by 0.41 percent. Top gainers in the sector included Kandi Technologies Group Inc (NASDAQ: KNDI), Starwood Hotels & Resorts Worldwide Inc (NYSE: HOT), and Lifetime Brands Inc (NASDAQ: LCUT).

best stock buys: Paragon Offshore plc (PGNPQ)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Paragon Offshore’s (OTCPK:PGNPQ) former management’s audacious efforts to omit parts of the senior secured lenders by deeming them unimpaired and instead pay out the majority of the company’s cash to junior unsecured bondholders by presenting a set of entirely unrealistic business forecasts to the court. Fortunately, in case of Paragon Offshore, the bankruptcy judge recognized the framing and accordingly denied confirmation of the company’s plan of reorganization, effectively sending Paragon Offshore back to the drawing board. Consequently, management was ousted after the failure. I have covered the Paragon Offshore saga in a series of articles over the past few quarters, so interested investors might want to take a look at this highly fascinating and still evolving case study.

  • [By SEEKINGALPHA.COM]

    With even brand new rigs struggling to find work, the jig was soon up for owners of old equipment, like Paragon Offshore (OTCPK:PGNPQ), which is currently undergoing its second debt restructuring in less than three years of independent existence. Likewise, drillers with a fondness for aggressive use of debt were soon in trouble, most notably, former high-flier Seadrill (SDRL) and its little brother North Atlantic Drilling (NADL), which will no doubt file for restructuring within months. As a consequence of the crisis, the OSD industry now has a number of participants without a large debt burden, either new entrants like Borr Drilling, or established competitors that have had debt reduced in a restructuring, such as Ocean Rig (ORIG), to be followed within this year by others, almost certainly including each of SDRL, NADL, and Pacific Drilling (PACD).

Leave a Reply

Your email address will not be published. Required fields are marked *